Sarepta Therapeutics (NASDAQ:SRPT) Given New $35.00 Price Target at Robert W. Baird

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target lifted by research analysts at Robert W. Baird from $30.00 to $35.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Robert W. Baird's price target indicates a potential upside of 148.76% from the company's previous close.

Other analysts have also issued research reports about the company. Royal Bank Of Canada cut their price target on Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating and set a $29.00 price target for the company. in a report on Tuesday, June 17th. Oppenheimer cut their price target on Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a report on Friday, June 20th. BMO Capital Markets lowered Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $120.00 to $70.00 in a research note on Monday, June 16th. Finally, Barclays dropped their price objective on Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a research note on Tuesday, June 17th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $56.50.

Sarepta Therapeutics Stock Down 36.0%

Shares of SRPT traded down $7.90 on Thursday, reaching $14.07. The stock had a trading volume of 76,793,187 shares, compared to its average volume of 2,685,783. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -5.23 and a beta of 0.45. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02. The company has a 50-day simple moving average of $28.86 and a 200-day simple moving average of $69.08. Sarepta Therapeutics has a 12-month low of $12.88 and a 12-month high of $150.48.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm's quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.73 EPS. Sell-side analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Generali Investments CEE investicni spolecnost a.s. raised its position in Sarepta Therapeutics by 5,166.3% during the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 105,326 shares of the biotechnology company's stock valued at $1,801,000 after purchasing an additional 103,326 shares during the period. Janney Montgomery Scott LLC raised its position in Sarepta Therapeutics by 123.5% during the second quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company's stock valued at $492,000 after purchasing an additional 15,882 shares during the period. Tempus Wealth Planning LLC raised its position in Sarepta Therapeutics by 475.8% during the second quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock valued at $353,000 after purchasing an additional 17,070 shares during the period. Public Employees Retirement System of Ohio raised its position in Sarepta Therapeutics by 2.2% during the second quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company's stock valued at $492,000 after purchasing an additional 607 shares during the period. Finally, Assenagon Asset Management S.A. raised its position in Sarepta Therapeutics by 21.8% during the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after purchasing an additional 155,358 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.